Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.

Feasibility assessed not started

Can this study realistically enroll — sites, patients, timeline?

Protocol drafted & medically reviewed not started

A protocol draft exists and has been through medical review.

Sites activation-ready not started

Every site passes the essential-document checklist.

Candidates matched not started

The partner matching engine has proposed candidates (import is human-gated).

Sites risk-scored not started

Risk-based monitoring pass; high-risk sites get a proposed visit.

Data cleaned not started

Consistency rules swept the EDC; deterministic queries auto-resolved.

Safety reports triaged not started

Every reported adverse event triaged; serious ones with a physician.

Dropout risk scored not started

Active patients scored; at-risk cohort proposed for outreach.

Drug supply forecast not started

Kits required modeled from enrollment and retention (partner IRT).

TLFs generated & validated not started

Tables/listings/figures from live data, pending double-programming validation.

CSR drafted & signed off not started

Clinical study report skeleton assembled; medical sign-off required.

TMF inspection-ready not started

Trial master file completeness audited; gaps filed as QA findings.